de Garidel Marc 4
4 · CinCor Pharma, Inc. · Filed Jan 30, 2023
Insider Transaction Report
Form 4
de Garidel Marc
DirectorChief Executive Officer
Transactions
- Award
Common Stock
2023-01-26+200,000→ 212,500 total
Footnotes (1)
- [F1]Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of the Issuer's common stock. One-fourth (1/4) of the RSUs shall vest on January 26, 2024 and the remaining RSUs shall vest in three (3) equal annual installments thereafter, subject to the Reporting Person's continuous service through each such vesting date; provided that, in the event the previously announced pending acquisition of the Issuer by AstraZeneca PLC occurs, 50% of the RSUs shall vest immediately prior to the closing of such transaction, subject to the Reporting Person's continuous service through such date, and the remaining 50% of the RSUs shall be cancelled as of such date.